As of 2026-06-26, BridgeBio Pharma, Inc. Common Stock (BBIO) has a 3-month relative strength percentile of 34 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.7%, relative volume 9.27×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ADR% (20d)avg daily range
3.7%
ATR(14)14-day EMA
$2.65
ATR%ATR as % of close
3.78%
Beta vs SPY90d rolling
0.85
1-ADR stoprisk from close $70.24
$67.65−3.7%
COMPUTED · AS OF 2026-06-26
Pattern read
BBIO is in a stage 3 topping pattern, week 4. Currently in a 107-day base; basing ADR 4.5% (broad 4.0%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 1.9% / 3.4%.
Pure factual computation. Not a recommendation. See stage analysis.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
BBIO ranks at the 66th percentile over 1 month, 34th percentile over 3 months, 40th percentile over 6 months, 80th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
BBIO is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
BBIO currently shows a 20-day average daily range (ADR%) of 3.7%, a 90-day beta versus the S&P 500 of 0.85. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes BBIO's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what BBIO has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
BBIO most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-07. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
10y · since 2022
Best monthJulon averageavg +27.71% · 75% win · n 4
Worst monthApron averageavg -9.76% · 20% win · n 5